Input 2021.02.04 20:09
–
According to the Korea Exchange on the 4th, SK Bioscience was confirmed as eligible for listing as it met the requirements as a result of preliminary examination for listing on the KOSPI. SK Bioscience requested a preliminary review in December last year, and it has crossed the threshold of the exchange in two months. In the near future, it is expected to submit a stock report containing the schedule of demand forecasting and so on to open a public offering.
SK Biosciences in July 2018 SK chemicals (285130)Spun off from. SK Chemicals owns 98%.
It mainly focuses on manufacturing and selling vaccines. Self-developed vaccines such as SkyCellflu (flu), Skyzoster (shingles) and Skyvaricella (chickenpox) account for more than 40% of total sales. Last year, it signed a contract for development and production (CDMO) with NovaVax, and received attention as the consignment production (CMO) of AstraZeneca’s vaccine.
As of 2019, SK Bioscience recorded sales of 183.9 billion won, operating profit of 22.8 billion won, and net profit of 14.7 billion won.
–
– .
